Skip to main content

Advertisement

Log in

Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest

  • Research Article
  • Published:
Tumor Biology

Abstract

Histone deacetylases (HDACs) play a critical role in the proliferation, differentiation, and apoptosis of cancer cells. An obstacle for the application of HDAC inhibitors as effective anti-cancer therapeutics is that our current knowledge on the contributions of different HDACs in various cancer types remains scarce. The present study reported that the mRNA and protein levels of HDAC5 were up-regulated in human hepatocellular carcinoma (HCC) tissues and cells as shown by quantitative real-time PCR and Western blot. MTT assay and BrdU incorporation assay showed that the down-regulation of HDAC5 inhibited cell proliferation in HepG2, Hep3B, and Huh7 cell lines. Data from in vivo xenograft tumorigenesis model also demonstrated the anti-proliferative effect of HDAC5 depletion on tumor cell growth. Furthermore, the suppression of HDAC5 promoted cell apoptosis and induced G1-phase cell cycle arrest in HCC cells. On the molecular level, we observed altered expression of apoptosis-related proteins such as p53, bax, bcl-2, cyto C, and caspase 3 in HDAC5-shRNA-transfected cells. Knockdown of HDAC5 led to a significant up-regulation of p21 and down-regulation of cyclin D1 and CDK2/4/6. We also found that the down-regulation of HDAC5 substantially increased p53 stability and promoted its nuclear localization and transcriptional activity. Our study suggested that knockdown of HDAC5 could inhibit cancer cell proliferation by the induction of cell cycle arrest and apoptosis; thus, suppression of HDAC5 may be a viable option for treating HCC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–27.

    Article  CAS  PubMed  Google Scholar 

  2. Yang Y, Jin C, Li H, et al. Improved radiosensitizing effect of the combination of etanidazole and paclitaxel for hepatocellular carcinoma in vivo. Exp Ther Med. 2012;3:299–303.

    CAS  PubMed Central  PubMed  Google Scholar 

  3. Zhang C, Ling Y, Zhang C, et al. The silencing of reck gene is associated with promoter hypermethylation and poor survival in hepatocellular carcinoma. Int J Biol Sci. 2012;8:451–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Minagawa M, Makuuchi M, Takayama T, et al. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg. 2003;238:703–10.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Johnson FM, Saigal B, Talpaz M, et al. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res. 2005;11:6924–32.

    Article  CAS  PubMed  Google Scholar 

  6. Yan K, Zhang C, Feng J, et al. Induction of G1 cell cycle arrest and apoptosis by berberine in bladder cancer cells. Eur J Pharmacol. 2011;661:1–7.

    Article  CAS  PubMed  Google Scholar 

  7. West AC, Mattarollo SR, Shortt J, et al. An intact immune system is required for the anticancer activities of histone deacetylase inhibitors. Cancer Res. 2013;73:7265–76.

    Article  CAS  PubMed  Google Scholar 

  8. Sebastian C, Zwaans BM, Silberman DM, et al. The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell. 2012;151:1185–99.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Mottet D, Pirotte S, Lamour V, et al. HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene. 2009;28:243–56.

    Article  CAS  PubMed  Google Scholar 

  10. Wilson AJ, Byun DS, Nasser S, et al. HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell. 2008;19:4062–75.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Zhu C, Chen Q, Xie Z, et al. The role of histone deacetylase 7 (HDAC7) in cancer cell proliferation: regulation on c-Myc. J Mol Med (Berl). 2011;89:279–89.

    Article  CAS  Google Scholar 

  12. Wagner JM, Hackanson B, Lubbert M, et al. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics. 2010;1:117–36.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Zhang Y, Matkovich SJ, Duan X, et al. Receptor-independent protein kinase c alpha (PKCalpha) signaling by calpain-generated free catalytic domains induces HDAC5 nuclear export and regulates cardiac transcription. J Biol Chem. 2011;286:26943–51.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Osada H, Tatematsu Y, Saito H, et al. Reduced expression of class ii histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer. 2004;112:26–32.

    Article  CAS  PubMed  Google Scholar 

  15. Milde T, Oehme I, Korshunov A, et al. HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. Clin Cancer Res. 2010;16:3240–52.

    Article  CAS  PubMed  Google Scholar 

  16. Lachenmayer A, Toffanin S, Cabellos L, et al. Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the hdac inhibitor panobinostat with sorafenib. J Hepatol. 2012;56:1343–50.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Liu H, Li P, Zhai Y, et al. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol. 2010;16:4410–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Glaser KB, Li J, Staver MJ, et al. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun. 2003;310:529–36.

    Article  CAS  PubMed  Google Scholar 

  19. Valenzuela-Fernandez A, Cabrero JR, Serrador JM, et al. HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol. 2008;18:291–7.

    Article  CAS  PubMed  Google Scholar 

  20. Lee CK, Wang S, Huang X, et al. HDAC inhibition synergistically enhances alkylator-induced dna damage responses and apoptosis in multiple myeloma cells. Cancer Lett. 2010;296:233–40.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Peixoto P, Castronovo V, Matheus N, et al. HDAC5 is required for maintenance of pericentric heterochromatin, and controls cell-cycle progression and survival of human cancer cells. Cell Death Differ. 2012;19:1239–52.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. La Vignera S, Condorelli R, Vicari E, et al. Effects of varicocelectomy on sperm DNA fragmentation, mitochondrial function, chromatin condensation, and apoptosis. J Androl. 2012;33:389–96.

    Article  PubMed  Google Scholar 

  23. Ren W, Beebe SJ. An apoptosis targeted stimulus with nanosecond pulsed electric fields (nsPEFs) in E4 squamous cell carcinoma. Apoptosis. 2011;16:382–93.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Weinert T, Hopper AK. tRNA traffic meets a cell-cycle checkpoint. Cell. 2007;131:838–40.

    Article  CAS  PubMed  Google Scholar 

  25. Bai Y, Mao QQ, Qin J, et al. Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Sci. 2010;101:488–93.

    Article  CAS  PubMed  Google Scholar 

  26. Yang L, Besschetnova TY, Brooks CR, et al. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med. 2010;16(535–43):1–143.

    Google Scholar 

  27. McKinsey TA, Zhang CL, Lu J, et al. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature. 2000;408:106–11.

    Article  CAS  PubMed  Google Scholar 

  28. Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2007;1:19–25.

    Article  CAS  PubMed  Google Scholar 

  29. Richon VM, Sandhoff TW, Rifkind RA, et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A. 2000;97:10014–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Zhao Y, Tan J, Zhuang L, et al. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci U S A. 2005;102:16090–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Kramer OH, Gottlicher M, Heinzel T. Histone deacetylase as a therapeutic target. Trends Endocrinol Metab. 2001;12:294–300.

    Article  CAS  PubMed  Google Scholar 

  32. Marks PA, Richon VM, Breslow R, et al. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol. 2001;13:477–83.

    Article  CAS  PubMed  Google Scholar 

  33. Hu W, Ge Y, Ojcius DM, et al. P53 signalling controls cell cycle arrest and caspase-independent apoptosis in macrophages infected with pathogenic leptospira species. Cell Microbiol. 2013;15:1642–59.

    PubMed  Google Scholar 

  34. Qiao D, Meyer K, Friedl A. Glypican-1 stimulates Skp2 autoinduction loop and G1/S transition in endothelial cells. J Biol Chem. 2012;287:5898–909.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Abe K, Naruse C, Kato T, et al. Loss of heterochromatin protein 1 gamma reduces the number of primordial germ cells via impaired cell cycle progression in mice. Biol Reprod. 2011;85:1013–24.

    Article  CAS  PubMed  Google Scholar 

  36. Jin L, Li C, Xu Y, et al. Epigallocatechin gallate promotes p53 accumulation and activity via the inhibition of MDM2-mediated p53 ubiquitination in human lung cancer cells. Oncol Rep. 2013;29:1983–90.

    CAS  PubMed  Google Scholar 

  37. Yuan J, Luo K, Zhang L, et al. Usp10 regulates p53 localization and stability by deubiquitinating p53. Cell. 2010;140:384–96.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

This research was supported by the State Major Science and Technology Special Projects during the period of China State 12th 5-year plan (grant 2012ZX10002).

Conflicts of interest

None

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yu Chen.

Additional information

Jian Fan and Bin Lou contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fan, J., Lou, B., Chen, W. et al. Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest. Tumor Biol. 35, 11523–11532 (2014). https://doi.org/10.1007/s13277-014-2358-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2358-2

Keywords

Navigation